BioGaia AB (publ) (BIOG-B.ST)
SEK 101.1
(2.17%)
SEK 101.1
(2.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.53 Billion SEK | -4.57% |
| 2022 | -1.46 Billion SEK | 0.41% |
| 2021 | -1.47 Billion SEK | -1.05% |
| 2020 | -1.45 Billion SEK | -611.94% |
| 2019 | -204.93 Million SEK | 28.08% |
| 2018 | -284.96 Million SEK | 6.83% |
| 2017 | -305.85 Million SEK | -25.83% |
| 2016 | -243.06 Million SEK | -7.13% |
| 2015 | -226.88 Million SEK | -7.7% |
| 2014 | -210.66 Million SEK | 10.08% |
| 2013 | -234.27 Million SEK | 37.52% |
| 2012 | -374.97 Million SEK | -118.6% |
| 2011 | -171.53 Million SEK | -17.59% |
| 2010 | -145.87 Million SEK | -46.37% |
| 2009 | -99.66 Million SEK | -71.46% |
| 2008 | -58.12 Million SEK | -35.25% |
| 2007 | -42.97 Million SEK | -8.2% |
| 2006 | -39.71 Million SEK | 12.45% |
| 2005 | -45.36 Million SEK | 27.03% |
| 2004 | -62.17 Million SEK | 26.9% |
| 2003 | -85.05 Million SEK | 24.54% |
| 2002 | -112.71 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -1.11 Billion SEK | -10.6% |
| 2024 Q1 | -1.59 Billion SEK | -3.65% |
| 2024 Q2 | -1 Billion SEK | 36.68% |
| 2023 FY | -1.53 Billion SEK | -4.57% |
| 2023 Q4 | -1.53 Billion SEK | -5.7% |
| 2023 Q1 | -1.58 Billion SEK | -7.67% |
| 2023 Q3 | -1.45 Billion SEK | -6.06% |
| 2023 Q2 | -1.36 Billion SEK | 13.36% |
| 2022 Q3 | -1.4 Billion SEK | -3.4% |
| 2022 Q4 | -1.46 Billion SEK | -4.7% |
| 2022 FY | -1.46 Billion SEK | 0.41% |
| 2022 Q1 | -1.46 Billion SEK | 0.6% |
| 2022 Q2 | -1.35 Billion SEK | 7.44% |
| 2021 Q1 | -1.47 Billion SEK | -0.76% |
| 2021 FY | -1.47 Billion SEK | -1.05% |
| 2021 Q2 | -1.45 Billion SEK | 1.17% |
| 2021 Q4 | -1.47 Billion SEK | 2.76% |
| 2021 Q3 | -1.51 Billion SEK | -4.35% |
| 2020 Q3 | -292.38 Million SEK | -20.55% |
| 2020 Q2 | -242.54 Million SEK | 14.64% |
| 2020 Q4 | -1.45 Billion SEK | -398.99% |
| 2020 Q1 | -284.13 Million SEK | -38.65% |
| 2020 FY | -1.45 Billion SEK | -611.94% |
| 2019 Q1 | -298.86 Million SEK | -4.88% |
| 2019 FY | -204.93 Million SEK | 28.08% |
| 2019 Q4 | -204.93 Million SEK | -2.08% |
| 2019 Q3 | -200.76 Million SEK | -37.37% |
| 2019 Q2 | -146.15 Million SEK | 51.1% |
| 2018 Q4 | -284.96 Million SEK | -10.67% |
| 2018 Q1 | -229.93 Million SEK | 24.82% |
| 2018 Q2 | -215.47 Million SEK | 6.29% |
| 2018 Q3 | -257.49 Million SEK | -19.5% |
| 2018 FY | -284.96 Million SEK | 6.83% |
| 2017 Q2 | -99.1 Million SEK | 53.94% |
| 2017 FY | -305.85 Million SEK | -25.83% |
| 2017 Q4 | -305.85 Million SEK | -125.09% |
| 2017 Q3 | -135.87 Million SEK | -37.1% |
| 2017 Q1 | -215.17 Million SEK | 11.48% |
| 2016 Q4 | -243.06 Million SEK | -102.54% |
| 2016 FY | -243.06 Million SEK | -7.13% |
| 2016 Q3 | -120.01 Million SEK | -71.64% |
| 2016 Q2 | -69.91 Million SEK | 53.4% |
| 2016 Q1 | -150.04 Million SEK | 33.87% |
| 2015 Q4 | -226.88 Million SEK | -55.65% |
| 2015 Q2 | -117.88 Million SEK | 29.31% |
| 2015 Q3 | -145.76 Million SEK | -23.66% |
| 2015 FY | -226.88 Million SEK | -7.7% |
| 2015 Q1 | -166.75 Million SEK | 20.85% |
| 2014 FY | -210.66 Million SEK | 10.08% |
| 2014 Q2 | -154.18 Million SEK | 42.72% |
| 2014 Q3 | -160.83 Million SEK | -4.31% |
| 2014 Q4 | -210.66 Million SEK | -30.98% |
| 2014 Q1 | -269.18 Million SEK | -14.9% |
| 2013 FY | -234.27 Million SEK | 37.52% |
| 2013 Q1 | -358.54 Million SEK | 4.38% |
| 2013 Q4 | -234.27 Million SEK | -14.75% |
| 2013 Q3 | -204.16 Million SEK | 3.03% |
| 2013 Q2 | -210.54 Million SEK | 41.28% |
| 2012 Q1 | -401.27 Million SEK | -133.93% |
| 2012 Q2 | -300.07 Million SEK | 25.22% |
| 2012 Q4 | -374.97 Million SEK | -17.2% |
| 2012 Q3 | -319.95 Million SEK | -6.62% |
| 2012 FY | -374.97 Million SEK | -118.6% |
| 2011 FY | -171.53 Million SEK | -17.59% |
| 2011 Q2 | -82.37 Million SEK | 44.53% |
| 2011 Q1 | -148.51 Million SEK | -1.81% |
| 2011 Q4 | -171.53 Million SEK | -45.67% |
| 2011 Q3 | -117.75 Million SEK | -42.95% |
| 2010 Q2 | -75.26 Million SEK | 15.28% |
| 2010 Q3 | -125.71 Million SEK | -67.02% |
| 2010 FY | -145.87 Million SEK | -46.37% |
| 2010 Q4 | -145.87 Million SEK | -16.04% |
| 2010 Q1 | -88.84 Million SEK | 10.85% |
| 2009 FY | -99.66 Million SEK | -71.46% |
| 2009 Q4 | -99.66 Million SEK | 0.0% |
| 2009 Q2 | -50.52 Million SEK | 0.0% |
| 2008 FY | -58.12 Million SEK | -35.25% |
| 2007 FY | -42.97 Million SEK | -8.2% |
| 2006 FY | -39.71 Million SEK | 12.45% |
| 2005 FY | -45.36 Million SEK | 27.03% |
| 2004 FY | -62.17 Million SEK | 26.9% |
| 2003 FY | -85.05 Million SEK | 24.54% |
| 2002 FY | -112.71 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AcuCort AB | -19.24 Million SEK | -7878.549% |
| AlzeCure Pharma AB (publ) | -29.1 Million SEK | -5176.261% |
| Enzymatica AB (publ) | 17.73 Million SEK | 8756.436% |
| Enorama Pharma AB (publ) | -5.71 Million SEK | -26756.603% |
| Gabather AB (publ) | -1.11 Million SEK | -137603.318% |
| Klaria Pharma Holding AB (publ.) | 17.68 Million SEK | 8781.889% |
| Moberg Pharma AB (publ) | -55.81 Million SEK | -2650.711% |
| Nanexa AB (publ) | -61.13 Million SEK | -2411.437% |
| Newbury Pharmaceuticals AB (publ) | -15.3 Million SEK | -9933.275% |
| ODI Pharma AB | -2.63 Million SEK | -58104.955% |
| Orexo AB (publ) | 302.8 Million SEK | 607.065% |
| Probi AB (publ) | -275.85 Million SEK | -456.598% |
| Swedencare AB (publ) | 1.42 Billion SEK | 208.027% |
| Swedish Orphan Biovitrum AB (publ) | 19.58 Billion SEK | 107.841% |
| Toleranzia AB | -17.45 Million SEK | -8696.792% |
| Vivesto AB | -1.29 Million SEK | -118097.998% |